(CGEM) Cullinan Oncology - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 937m USD | Total Return: 77.6% in 12m
Industry Rotation: -8.2
Avg Turnover: 12.7M
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
Cullinan Therapeutics (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune diseases and oncology. Its pipeline features several bispecific T cell engagers, including CLN-978 and Velinotamig, alongside Zipalertinib, an oral small-molecule inhibitor currently in Phase 2b trials for non-small cell lung cancer. The company utilizes a hub-and-spoke business model, establishing strategic partnerships with entities like Taiho Pharmaceutical and Adimab to share development risks and resources.
The biotechnology sector is characterized by high capital intensity and long regulatory lead times, where clinical trial outcomes serve as primary catalysts for valuation shifts. Cullinans recent rebranding from Cullinan Oncology reflects a strategic expansion into the immunology space, diversifying its clinical risk across multiple therapeutic areas. For a more granular look at the companys financial health and valuation metrics, consider reviewing the data on ValueRay.
Headquartered in Cambridge, Massachusetts, the company maintains a portfolio that targets specific genetic mutations and cell surface proteins. This precision medicine approach aims to improve efficacy while reducing off-target toxicity compared to traditional systemic treatments.
- CLN-978 clinical trial data determines entry into high-growth autoimmune disease markets
- Zipalertinib Phase 2b results drive regulatory path for lung cancer approval
- Strategic expansion into immunology shifts valuation beyond traditional oncology assets
- Partnership milestones with Taiho Pharmaceutical impact near-term cash flow and R&D funding
- Success of bispecific T-cell engager platform dictates long-term pipeline scalability
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -18.43 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.44 > 3% & CFO -178.6m > Net Income -221.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.2m) vs 12m ago 0.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.81 (Total Current Assets 361.4m - Total Current Liabilities 35.2m) / Total Assets 403.0m |
| B: -1.58 (Retained Earnings -637.8m / Total Assets 403.0m) |
| C: -0.48 (EBIT TTM -235.4m / Avg Total Assets 491.3m) |
| D: -17.32 (Book Value of Equity -637.6m / Total Liabilities 36.8m) |
| Altman-Z'' = -21.26 = D |
Over the past week, the price has changed by -13.44%, over one month by -1.69%, over three months by -0.07% and over the past year by +77.64%.
- StrongBuy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.6 | 125.7% |
P/S = 25.8559
P/B = 2.4437
Revenue TTM = 0.0 USD
EBIT TTM = -235.4m USD
EBITDA TTM = -235.1m USD
Long Term Debt = 1.66m USD (estimated: total debt 2.38m - short term 725k)
Short Term Debt = 725k USD (from shortTermDebt, last quarter)
Debt = 5.07m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.68m
Net Debt = -346.8m USD (calculated: Debt 5.07m - CCE 351.9m)
Enterprise Value = 590.4m USD (937.2m + Debt 5.07m - CCE 351.9m)
Interest Coverage Ratio = unknown (Ebit TTM -235.4m / Interest Expense TTM 0.0)
EV/FCF = -3.30x (Enterprise Value 590.4m / FCF TTM -178.7m)
FCF Yield = -30.26% (FCF TTM -178.7m / Enterprise Value 590.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 235k) / Revenue TTM)
Tobins Q-Ratio = 1.47 (Enterprise Value 590.4m / Total Assets 403.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.07m)
Taxrate = 21.0% (US default 21%)
NOPAT = -186.0m (EBIT -235.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.28 (Total Current Assets 361.4m / Total Current Liabilities 35.2m)
Debt / Equity = 0.01 (Debt 5.07m / totalStockholderEquity, last quarter 366.2m)
Debt / EBITDA = 1.48 (negative EBITDA) (Net Debt -346.8m / EBITDA -235.1m)
Debt / FCF = 1.94 (negative FCF - burning cash) (Net Debt -346.8m / FCF TTM -178.7m)
Total Stockholder Equity = 429.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.99% (Net Income -221.0m / Total Assets 403.0m)
RoE = -20.71% (Net Income TTM -221.0m / Total Stockholder Equity 1.07b)
RoCE = -22.02% (EBIT -235.4m / Capital Employed (Equity 1.07b + L.T.Debt 1.66m))
RoIC = -1.12k% (out of range, set to none) (NOPAT -186.0m / Invested Capital 16.7m)
WACC = 9.17% (E(937.2m)/V(942.3m) * Re(9.22%) + D(5.07m)/V(942.3m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 15.52%
[DCF] Fair Price = unknown (Cash Flow -178.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.49 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.85 | Chg30d=+3.87% | Revisions=+33% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.87 | Chg30d=+5.63% | Revisions=+33% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.12 | Chg30d=-1.99% | Revisions=+20% | GrowthEPS=+7.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.54 | Chg30d=+11.55% | Revisions=+33% | GrowthEPS=+18.4% | GrowthRev=+478.2%
[Analyst] Revisions Ratio: +33%